Abstract:Vascular dementia (VaD) is a neurodegenerative disease resulting from cerebral vascular obstruction, leading to cognitive impairment, and currently lacks effective treatment options. Due to its complex pathogenesis, multi‐target drug design (MTDLs) strategies are considered among the most promising therapeutic approaches. In this study, we designed and synthesized a series of novel indanone derivatives targeting targets related to vascular health and dementia. The results indicated that compound C5 exhibited excellent acetylcholinesterase inhibitory activity (IC50 = 1.16 ± 0.41 μM) and anti‐platelet aggregation activity (IC50 = 4.92 ± 0.10 μM) within ranges of 0.1‐1000 μM and 0.03‐300 μM, respectively, possibly mediated by molecular docking interactions. Furthermore, compound C5 demonstrated protective effects on cells at concentrations ≤50 μM, significantly reducing the release of nitric oxide (NO), tumor necrosis factor‐alpha (TNF‐α), and interleukin‐1 beta (IL‐1β) in a concentration‐dependent manner, showcasing its potent neuroinflammatory inhibitory effects. Anti‐inflammatory therapies are regarded as effective strategies for treating VaD. Therefore, compound C5 holds promise as a novel candidate drug for further investigation into the treatment of vascular dementia.

Design, Synthesis, and Anti‐Inflammatory Activity Evaluation of Novel Indanone Derivatives for the Treatment of Vascular Dementia